Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NVXC19

Vaccine · Immune activation · developed by Sanofi

Phase 3 Most advanced trial
SNY Developer
1 Registered trials

What is NVXC19?

NVXC19 is an intramuscularly injected dispersion studied for immunization against COVID-19 and influenza in healthy volunteers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
Sanofi (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07890454 Phase 3 Immunization Recruiting SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19 ImmunizationHealthy VolunteersImmunizationInfluenza Immunization

More from Sanofi

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind NVXC19

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.